

DESCRIPTION

Species Reactivity	Human
Specificity	Detects human CRBN in immunocytochemistry and immunohistochemistry.
Source	Monoclonal Mouse IgG _{2B} Clone # 978015
Purification	Protein A or G purified from hybridoma culture supernatant
Immunogen	Synthetic peptide Human CRBN Accession # Q96SW2
Conjugate	Alexa Fluor 700 Excitation Wavelength: 675-700 nm Emission Wavelength: 723 nm
Formulation	Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide
*Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions.	

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. [General Protocols](#) are available in the Technical Information section on our website.

Immunocytochemistry	Optimal dilution of this antibody should be experimentally determined.
Immunohistochemistry	Optimal dilution of this antibody should be experimentally determined.

PREPARATION AND STORAGE

Shipping	The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied

BACKGROUND

Cereblon (CRBN) is a substrate recognition component of an E3 protein ligase complex which mediates ubiquitination and proteasomal degradation of target proteins. In embryonic development, degradation of regulatory proteins is required for normal limb outgrowth. Thalidomide, a teratogenic drug prescribed to pregnant women in the 1950s, binds to CRBN in the E3 protein ligase complex. Despite its teratogenic effect, CRBN is used to treat multiple myeloma and complications of leprosy. Widely expressed, CRBN may play a role in memory and learning by regulating assembly and surface expression of large-conductance calcium-activated potassium channels in hippocampal neurons. Mutations in the CRBN gene is linked to the Mental Retardation, Autosomal Recessive2a (MR2A) form of mental retardation.

PRODUCT SPECIFIC NOTICES

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.